Sexual bladder perfusion chemotherapy (local chemotherapy) is usually recommended after surgery for renal pelvis cancer, and some patients may also receive concurrent systemic chemotherapy. Renal pelvis cancer originates from urinary tract epithelium, and its biological characteristics are multipoint occurrence and easy recurrence. Since the mucosa of ureter and bladder is also the urinary tract epithelium, it is often accompanied by tumors of ureter and bladder. In order to avoid the possibility of bladder tumors, postoperative bladder instillation is routinely required, and the main bladder instillation drugs are capillarubicin, mitomycin and so on. In addition, domestic guidelines recommend that, if renal function permits, platinum-based neoadjuvant chemotherapy or adjuvant chemotherapy can be chosen for patients with progressive stages in the perioperative period. Studies have also shown that postoperative recurrence-free survival of patients with T2 stage and above receiving gemcitabine combined with cisplatin adjuvant chemotherapy is significantly better than that of the non-chemotherapy group. Therefore, patients with renal pelvis cancer can receive bladder perfusion chemotherapy combined with systemic chemotherapy after surgery. However, it is recommended to go to regular hospitals to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate treatment plan to avoid delaying the condition.